Nazartinib

Drug Profile

Nazartinib

Alternative Names: EGF-816; EGFRmut-TKI EGF816

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 27 Jan 2017 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Belgium (PO) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-I/II for Non-small cell lung cancer (Late-stage disease, Monotherapy) in France, Belgium, Taiwan, South Korea, Japan, USA, Spain, Germany, Singapore, Canada (PO) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Monotherapy) in France, Belgium, Taiwan, South Korea, Japan, USA, Spain, Germany, Singapore, Canada (PO) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top